Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1996 Oct;51(10):989–992. doi: 10.1136/thx.51.10.989

Effect of regular terbutaline on the airway response to inhaled budesonide.

P J Wilding 1, M M Clark 1, J Oborne 1, J A Bennett 1, A E Tattersfield 1
PMCID: PMC472646  PMID: 8977598

Abstract

BACKGROUND: The rebound increase in bronchial reactivity and fall in forced expiratory volume in one second (FEV1) following treatment with beta agonists seen in several studies has occurred regardless of concurrent steroid therapy. Little is known about the effect of adding beta agonists to corticosteroids, but in a recent study regular treatment with terbutaline appeared to reduce some of the beneficial effects of budesonide. The effects of budesonide alone and in combination with regular terbutaline treatment on lung function, symptom scores, and bronchial reactivity were therefore examined. METHODS: Sixteen subjects with mild stable asthma inhaled budesonide 800 micrograms twice daily for two periods of 14 days with terbutaline 1000 micrograms three times daily or placebo in a double blind crossover fashion. FEV1 and the dose of histamine or adenosine monophosphate (AMP) causing a 20% fall in FEV1 (PD20) were measured before and 12 hours after the final dose of treatment, and changes from baseline were compared. Seven day mean values for daily morning and evening peak expiratory flow (PEF) values, symptom scores, and rescue medication were compared before and during treatment. RESULTS: Morning and evening PEF rose more with budesonide plus terbutaline than with budesonide alone, with a mean difference of 19 l/min occurring in the evening (95% confidence interval (CI) 2 to 36). There was no difference in symptom scores during treatment. Following treatment the mean increase in FEV1 was 150 ml higher with budesonide alone (95% CI-10 to 300). There was no difference between treatments in change in histamine and AMP PD20. CONCLUSIONS: Evening PEF was greater when budesonide was combined with regular terbutaline. There was no evidence of a difference in bronchial reactivity following the two treatment regimens. The findings of a previous study were not confirmed as the reduction in FEV1 after budesonide and terbutaline was smaller and not statistically significant. Further work is needed to determine whether this disparity in findings in the two studies is due to a type 2 statistical error in this study or a spurious finding in the previous study.

Full text

PDF
989

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Crane J., Pearce N., Flatt A., Burgess C., Jackson R., Kwong T., Ball M., Beasley R. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet. 1989 Apr 29;1(8644):917–922. doi: 10.1016/s0140-6736(89)92505-1. [DOI] [PubMed] [Google Scholar]
  2. D'Alonzo G. E., Nathan R. A., Henochowicz S., Morris R. J., Ratner P., Rennard S. I. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. JAMA. 1994 May 11;271(18):1412–1416. [PubMed] [Google Scholar]
  3. Dahl R., Pedersen B., Hägglöf B. Nocturnal asthma: effect of treatment with oral sustained-release terbutaline, inhaled budesonide, and the two in combination. J Allergy Clin Immunol. 1989 Apr;83(4):811–815. doi: 10.1016/0091-6749(89)90019-5. [DOI] [PubMed] [Google Scholar]
  4. Grainger J., Woodman K., Pearce N., Crane J., Burgess C., Keane A., Beasley R. Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study. Thorax. 1991 Feb;46(2):105–111. doi: 10.1136/thx.46.2.105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Harvey J. E., Tattersfield A. E. Airway response to salbutamol: effect of regular salbutamol inhalations in normal, atopic, and asthmatic subjects. Thorax. 1982 Apr;37(4):280–287. doi: 10.1136/thx.37.4.280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Higgins B. G., Britton J. R., Chinn S., Jones T. D., Jenkinson D., Burney P. G., Tattersfield A. E. The distribution of peak expiratory flow variability in a population sample. Am Rev Respir Dis. 1989 Nov;140(5):1368–1372. doi: 10.1164/ajrccm/140.5.1368. [DOI] [PubMed] [Google Scholar]
  7. Inman W. H., Adelstein A. M. Rise and fall of asthma mortality in England and Wales in relation to use of pressurised aerosols. Lancet. 1969 Aug 9;2(7615):279–285. doi: 10.1016/s0140-6736(69)90051-8. [DOI] [PubMed] [Google Scholar]
  8. Kerrebijn K. F., van Essen-Zandvliet E. E., Neijens H. J. Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma. J Allergy Clin Immunol. 1987 Apr;79(4):653–659. doi: 10.1016/s0091-6749(87)80163-x. [DOI] [PubMed] [Google Scholar]
  9. Kraan J., Koëter G. H., vd Mark T. W., Sluiter H. J., de Vries K. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J Allergy Clin Immunol. 1985 Oct;76(4):628–636. doi: 10.1016/0091-6749(85)90786-9. [DOI] [PubMed] [Google Scholar]
  10. Pearce N., Grainger J., Atkinson M., Crane J., Burgess C., Culling C., Windom H., Beasley R. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. Thorax. 1990 Mar;45(3):170–175. doi: 10.1136/thx.45.3.170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Pearlman D. S., Chervinsky P., LaForce C., Seltzer J. M., Southern D. L., Kemp J. P., Dockhorn R. J., Grossman J., Liddle R. F., Yancey S. W. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med. 1992 Nov 12;327(20):1420–1425. doi: 10.1056/NEJM199211123272004. [DOI] [PubMed] [Google Scholar]
  12. Sears M. R., Taylor D. R., Print C. G., Lake D. C., Li Q. Q., Flannery E. M., Yates D. M., Lucas M. K., Herbison G. P. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet. 1990 Dec 8;336(8728):1391–1396. doi: 10.1016/0140-6736(90)93098-a. [DOI] [PubMed] [Google Scholar]
  13. Speizer F. E., Doll R., Heaf P. Observations on recent increase in mortality from asthma. Br Med J. 1968 Feb 10;1(5588):335–339. doi: 10.1136/bmj.1.5588.335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Trembath P. W., Greenacre J. K., Anderson M., Dimmock S., Mansfield L., Wadsworth J., Green M. Comparison of four weeks' treatment with fenoterol and terbutaline aerosols in adult asthmatics. A double-blind crossover study. J Allergy Clin Immunol. 1979 Jun;63(6):395–400. doi: 10.1016/0091-6749(79)90212-4. [DOI] [PubMed] [Google Scholar]
  15. VanArsdel P. P., Jr, Schaffrin R. M., Rosenblatt J., Sprenkle A. C., Altman L. C. Evaluation of oral fenoterol in chronic asthmatic patients. Chest. 1978 Jun;73(6 Suppl):997–998. doi: 10.1378/chest.73.6_supplement.997. [DOI] [PubMed] [Google Scholar]
  16. Vathenen A. S., Knox A. J., Higgins B. G., Britton J. R., Tattersfield A. E. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet. 1988 Mar 12;1(8585):554–558. doi: 10.1016/s0140-6736(88)91352-9. [DOI] [PubMed] [Google Scholar]
  17. Wahedna I., Wong C. S., Wisniewski A. F., Pavord I. D., Tattersfield A. E. Asthma control during and after cessation of regular beta 2-agonist treatment. Am Rev Respir Dis. 1993 Sep;148(3):707–712. doi: 10.1164/ajrccm/148.3.707. [DOI] [PubMed] [Google Scholar]
  18. Wong C. S., Wahedna I., Pavord I. D., Tattersfield A. E. Effect of regular terbutaline and budesonide on bronchial reactivity to allergen challenge. Am J Respir Crit Care Med. 1994 Nov;150(5 Pt 1):1268–1273. doi: 10.1164/ajrccm.150.5.7952551. [DOI] [PubMed] [Google Scholar]
  19. van Schayck C. P., Dompeling E., van Herwaarden C. L., Folgering H., Verbeek A. L., van der Hoogen H. J., van Weel C. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study. BMJ. 1991 Dec 7;303(6815):1426–1431. doi: 10.1136/bmj.303.6815.1426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. van Schayck C. P., Graafsma S. J., Visch M. B., Dompeling E., van Weel C., van Herwaarden C. L. Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol. J Allergy Clin Immunol. 1990 Nov;86(5):793–800. doi: 10.1016/s0091-6749(05)80185-x. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES